Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
    • Clinic Portal
      • +0034963905310
    • Request Information
    • +34 96 390 53 10
    • Part of brands: |
    InternationalInternational
    • Country/Region
      • Part of brands: |
      • We guide you
        • Fertility
          • What to do if…
        • Prevent Inherited Diseases
          • Carrier Genetic Test
        • Worry-free Pregnancy
          • NACE
          • Prenatal Diagnostics
          • Newborn Health
      • Reproductive Health
        • Specialists
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • POC
          • SAT
          • Newborn Screening
        • Patients
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • SAT
          • POC
      • Diagnostics
      • About us
        • Igenomix Research
        • About Igenomix
        • Igenomix Worldwide
      • Academy
      • Blog
      Genomics Precision Diagnostic > Gene Analysis > NGS​ – Next Generation Sequencing

      NGS​ – Next Generation Sequencing

      Specific technology designed to detect DNA sequence variations in a gene or genomic region
      Overview
      Reporting
      Methodology
      Sample Requirements
      Limitations

      Overview

      • Description
      • Indication
      • Aplication
      • NGS Sequencing is a cost-effective technology for the diagnostic of mutations affecting to the entire coding region of a gen or small set of genes. 

      NGS sequencing is recommended for patients with:

      • Distinctive clinical features for a monogenic disease.
      • Family history of a monogenic diseases.

      The applications of NGS Sequencing include:

      • Identify the molecular cause of a monogenic diseases.

      Reporting & Results

      Test results are interpreted based on the recommendations and guidelines of the American College of Medical Genetics and Genomics (ACMG) and the European Society of Human Genetics (ESHG) as described below. 

        Different type of results can be obtained:

        • Pathogenic or likely pathogenic variant has been identified
        • The identification of a pathogenic or probably pathogenic variant associated with the clinical phenotype under study indicates that the result is compatible with the diagnosis of that disease or clinical condition. 
        • This scenario will allow to provide genetic counselling or personal guidance regarding possible medical treatments, disease progression, reproductive-/prevention-strategies and potential implications for other family members. 
        • NO Pathogenic or likely pathogenic variant has been identified
        • The absence of pathogenic or probably pathogenic variants associated with the clinical phenotype under study indicates that the molecular cause of the disease or condition has not been identified. This result does not confirm nor rule out the clinical indication of the test and does not guarantee that the individual will be healthy or free from other genetic disorders or medical conditions. For this reason, this result does not eliminate the risk for future offspring. A negative result may be explained by several causes, including limited genetic knowledge and limitations associated to the used methodology. 
        • Inconclusive / Variant of Uncertain Significance (VUS)
        • A “variant of uncertain significance” (VUS) is a genetic change whose clinical impact on the patient is not yet known. The presence of a VUS does not clarify whether the patient has an increased risk to develop the genetic disease or if it could be a normal genetic variant. Further analysis may be recommended, including testing both parents as well as other affected and unaffected family members. Sometimes, performing ancillary tests is necessary to prove the phenotype that the proband presents with. Detailed medical records or information from other family members also may be needed to help clarify the result. 
        • Result interpretation is based on currently available information in the medical literature, research, and scientific databases. Because the literature, medical and scientific knowledge are constantly changing, new information that becomes available in the future may replace or add to the information that Igenomix used to interpret the results. Re-analysis of the results in previously issued reports considering new evidence is not routinely performed but is available upon request. This result does not confirm nor rule out the clinical indication of the test and does not guarantee that the individual will be healthy or free from other genetic disorders or medical conditions. For this reason, this result does not eliminate the risk for future offspring. 

      Sample Requirements

       For Prenatal Diagnostic:  

      • Previous contact with the laboratory is strongly recommended to properly plan the case, prenatal deadlines and anticipate possible inconvenient 
      • Maternal blood sample must be sent with all products of conception, CVS and Amnio samples.  
      • Other family samples could be requested as positive control samples. 
      • Priority will be given to all prenatal samples. 

      A thorough labelling of the tube with unique identifying information is required, incorrect labelling can lead to rejection of the sample. The minimum required information to identify and accept a sample is: Patient’s full name, Date of birth, Gender and Medical Record Number.

      The ‘informed consent’ and the ‘test requisition from’ must be properly filled-in and signed by the patient and doctor.

      Methodology

      Limitations

      • NGS sequencing is a gene-specific test for the analysis of a small subset of genes.
      • NGS sequencing is able to identify mosaic mutations present in as low as 10% of the cells.
      • NGS sequencing cannot readily identify partial or whole gene deletions, because they cannot be amplified appropriately.

      Request Information

















    • WE GUIDE YOU

      Fertility
      Inherited diseases prevention
      Healthy pregnancy

      To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

      OUR SERVICES

      Genetic solutions
      For patients
      How to send a sample?
      User manual

      ABOUT US

      About Igenomix
      Contact
      Quality
      Complaints
      Work with us

      FOLLOW IGENOMIX

        + 96 390 53 10
        Write us
      • Argentina
      • Brazil
      • Canada
      • Chile
      • Colombia
      • Europe
      • France
      • Germany
      • India
      • Italy
      • Japan
      • Korea
      • Mexico
      • Perú
      • Russia
      • Spain
      • Taiwan
      • The Middle East
      • Turkey
      • United Kingdom
      • United States
      • Vietnam
      Country/Region

      [2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

      Request Information

















      • We guide you
        • Fertility
          • What to do if…
        • Prevent Inherited Diseases
          • Carrier Genetic Test
        • Worry-free Pregnancy
          • NACE
          • Prenatal Diagnostics
          • Newborn Health
      • Reproductive Health
        • Specialists
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • POC
          • SAT
          • Newborn Screening
        • Patients
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • SAT
          • POC
      • Diagnostics
      • About us
        • Igenomix Research
        • About Igenomix
        • Igenomix Worldwide
      • Academy
      • Blog
      • Country/Region
      • +34 96 390 53 10
      • Clinic Portal
      • Request Information

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in settings.

      International
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

      3rd Party Cookies

      This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

      Keeping this cookie enabled helps us to improve our website.

      Please enable Strictly Necessary Cookies first so that we can save your preferences!

      Cookie Policy

      More information about our Cookie Policy